Bulk Manufacturer of Controlled Substances Application: Cambridge IsotoPE LAB, 7635 [2015-02820]
Download as PDF
<![CDATA[
7635
Federal Register / Vol. 80, No. 28 / Wednesday, February 11, 2015 / Notices
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Deputy Assistant
Administrator of the DEA Office of
Diversion Control (‘‘Deputy Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix of subpart, R.
In accordance with 21 CFR
1301.33(a), this is notice that on
November 17, 2014, Siegfried USA,
LLC, 33 Industrial Park Road,
Pennsville, New Jersey 08070 applied to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Controlled substance
Schedule
Gamma
Hydroxybutyric
Acid
(2010).
Dihydromorphine (9145) ...............
Hydromorphinol (9301) .................
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Opium tincture (9630) ..................
Oxymorphone (9652) ...................
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Dated: February 5, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
or objections to the issuance of the
proposed registration in accordance
with 21 CFR 1301.33(a) on or before
April 13, 2015.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152. Request for hearings should be
sent to: Drug Enforcement
Administration, Attention: Hearing
Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Deputy Assistant
Administrator of the DEA Office of
Diversion Control (‘‘Deputy Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on August
12, 2014, Cambridge Isotope Lab, 50
Frontage Road, Andover, Massachusetts
01810 applied to be registered as a bulk
manufacturer of morphine (9300), a
basic class of controlled substance listed
in schedule II.
The company plans to utilize small
quantities of the listed controlled
substance in the preparation of
analytical standards.
Dated: February 5, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–02820 Filed 2–10–15; 8:45 am]
[FR Doc. 2015–02821 Filed 2–10–15; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
[Docket No. DEA–392]
tkelley on DSK3SPTVN1PROD with NOTICES
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: INSYS
Therapeutics, Inc.
Bulk Manufacturer of Controlled
Substances Application: Cambridge
IsotoPE LAB
ACTION:
ACTION:
Notice of application.
issuance of the proposed registration in
accordance with 21 CFR 1301.33(a) on
or before April 13, 2015.
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152. Request for hearings should be
sent to: Drug Enforcement
Administration, Attention: Hearing
Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152.
ADDRESSES:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, and
dispensers, of controlled substances
(other than final orders in connection
with suspension, denial, or revocation
of registration) has been redelegated to
the Deputy Assistant Administrator of
the DEA Office of Diversion Control
(‘‘Deputy Assistant Administrator’’)
pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on October
17, 2014, Insys Therapeutics, Inc., 2700
Oakmont, Round Rock, Texas 78665
applied to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
SUPPLEMENTARY INFORMATION:
Controlled substance
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
VerDate Sep<11>2014
17:07 Feb 10, 2015
Jkt 235001
Dated: February 5, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–02819 Filed 2–10–15; 8:45 am]
BILLING CODE 4410–09–P
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
PO 00000
Frm 00072
Fmt 4703
Sfmt 9990
I
I
The company plans to manufacture
bulk synthetic active pharmaceutical
ingredients (APIs) for product
development and distribution to its
customers. No other activity for this
drug code is authorized for this
registration.
DATES:
Registered bulk manufacturers of
the affected basic class, and applicants
therefore, may file written comments on
DATES:
Schedule
E:\FR\FM\11FEN1.SGM
11FEN1
]]>Agencies
[Federal Register Volume 80, Number 28 (Wednesday, February 11, 2015)]
[Notices]
[Page 7635]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-02820]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Cambridge
IsotoPE LAB
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic class, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration in accordance with 21 CFR
1301.33(a) on or before April 13, 2015.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/ODW,
8701 Morrissette Drive, Springfield, Virginia 22152. Request for
hearings should be sent to: Drug Enforcement Administration, Attention:
Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Deputy Assistant Administrator of the DEA Office of Diversion
Control (``Deputy Assistant Administrator'') pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on August
12, 2014, Cambridge Isotope Lab, 50 Frontage Road, Andover,
Massachusetts 01810 applied to be registered as a bulk manufacturer of
morphine (9300), a basic class of controlled substance listed in
schedule II.
The company plans to utilize small quantities of the listed
controlled substance in the preparation of analytical standards.
Dated: February 5, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015-02820 Filed 2-10-15; 8:45 am]
BILLING CODE 4410-09-P
